Literature DB >> 20519526

Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease.

Pierre Garcia1, Ihsen Youssef, Jo K Utvik, Sabrina Florent-Béchard, Vanassa Barthélémy, Catherine Malaplate-Armand, Badreddine Kriem, Christophe Stenger, Violette Koziel, Jean-Luc Olivier, Marie-Christine Escanye, Marine Hanse, Ahmad Allouche, Cédric Desbène, Frances T Yen, Rolf Bjerkvig, Thierry Oster, Simone P Niclou, Thierry Pillot.   

Abstract

The development of novel therapeutic strategies for Alzheimer's disease (AD) represents one of the biggest unmet medical needs today. Application of neurotrophic factors able to modulate neuronal survival and synaptic connectivity is a promising therapeutic approach for AD. We aimed to determine whether the loco-regional delivery of ciliary neurotrophic factor (CNTF) could prevent amyloid-beta (Abeta) oligomer-induced synaptic damages and associated cognitive impairments that typify AD. To ensure long-term administration of CNTF in the brain, we used recombinant cells secreting CNTF encapsulated in alginate polymers. The implantation of these bioreactors in the brain of Abeta oligomer-infused mice led to a continuous secretion of recombinant CNTF and was associated with the robust improvement of cognitive performances. Most importantly, CNTF led to full recovery of cognitive functions associated with the stabilization of synaptic protein levels in the Tg2576 AD mouse model. In vitro as well as in vivo, CNTF activated a Janus kinase/signal transducer and activator of transcription-mediated survival pathway that prevented synaptic and neuronal degeneration. These preclinical studies suggest that CNTF and/or CNTF receptor-associated pathways may have AD-modifying activity through protection against progressive Abeta-related memory deficits. Our data also encourage additional exploration of ex vivo gene transfer for the prevention and/or treatment of AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20519526      PMCID: PMC6632372          DOI: 10.1523/JNEUROSCI.4182-09.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  62 in total

1.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

Review 2.  Alzheimer's disease is a synaptic failure.

Authors:  Dennis J Selkoe
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

3.  Nerve growth factor gene therapy for Alzheimer's disease.

Authors:  Mark H Tuszynski; Leon Thal; Hoi-Sang U; Mary Margaret Pay; Armin Blesch; James Conner; H Lee Vahlsing
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

4.  The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Marcus A Westerman; Deirdre Cooper-Blacketer; Ami Mariash; Linda Kotilinek; Takeshi Kawarabayashi; Linda H Younkin; George A Carlson; Steven G Younkin; Karen H Ashe
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

5.  The nonfibrillar amyloid beta-peptide induces apoptotic neuronal cell death: involvement of its C-terminal fusogenic domain.

Authors:  T Pillot; B Drouet; S Queillé; C Labeur; J Vandekerchkhove; M Rosseneu; M Pinçon-Raymond; J Chambaz
Journal:  J Neurochem       Date:  1999-10       Impact factor: 5.372

6.  Local endostatin treatment of gliomas administered by microencapsulated producer cells.

Authors:  T A Read; D R Sorensen; R Mahesparan; P O Enger; R Timpl; B R Olsen; M H Hjelstuen; O Haraldseth; R Bjerkvig
Journal:  Nat Biotechnol       Date:  2001-01       Impact factor: 54.908

7.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

Review 8.  Cellular delivery of trophic factors for the treatment of Huntington's disease: is neuroprotection possible?

Authors:  J H Kordower; O Isacson; D F Emerich
Journal:  Exp Neurol       Date:  1999-09       Impact factor: 5.330

9.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

10.  Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability.

Authors:  Karie N Dahlgren; Arlene M Manelli; W Blaine Stine; Lorinda K Baker; Grant A Krafft; Mary Jo LaDu
Journal:  J Biol Chem       Date:  2002-06-10       Impact factor: 5.157

View more
  38 in total

1.  Subcutaneous implantation of microencapsulated cells overexpressing α-L-iduronidase for mucopolysaccharidosis type I treatment.

Authors:  Valeska Lizzi Lagranha; Barbara Zambiasi Martinelli; Guilherme Baldo; Giuseppe Ávila Testa; Talita Giacomet de Carvalho; Roberto Giugliani; Ursula Matte
Journal:  J Mater Sci Mater Med       Date:  2017-02-01       Impact factor: 3.896

2.  Xanthoceraside prevented synaptic loss and reversed learning-memory deficits in APP/PS1 transgenic mice.

Authors:  Ge Jin; Lin Zhu; Peng Liu; Qian Xu; Yue Qi; Xiaoyu Zhou; Jikai Xu; Xuefei Ji; Tianyan Chi; Libo Zou
Journal:  J Physiol Sci       Date:  2019-02-14       Impact factor: 2.781

Review 3.  The role of glial cells and the complement system in retinal diseases and Alzheimer's disease: common neural degeneration mechanisms.

Authors:  Hannah Harvey; Szonya Durant
Journal:  Exp Brain Res       Date:  2014-09-03       Impact factor: 1.972

Review 4.  The role of growth factors as a therapeutic approach to demyelinating disease.

Authors:  Yangyang Huang; Cheryl F Dreyfus
Journal:  Exp Neurol       Date:  2016-03-22       Impact factor: 5.330

5.  Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy.

Authors:  Anke Piechotta; Christoph Parthier; Martin Kleinschmidt; Kathrin Gnoth; Thierry Pillot; Inge Lues; Hans-Ulrich Demuth; Stephan Schilling; Jens-Ulrich Rahfeld; Milton T Stubbs
Journal:  J Biol Chem       Date:  2017-06-16       Impact factor: 5.157

Review 6.  Cell-mediated drug delivery.

Authors:  Elena V Batrakova; Howard E Gendelman; Alexander V Kabanov
Journal:  Expert Opin Drug Deliv       Date:  2011-02-24       Impact factor: 6.648

Review 7.  Encapsulated cell grafts to treat cellular deficiencies and dysfunction.

Authors:  N V Krishnamurthy; Barjor Gimi
Journal:  Crit Rev Biomed Eng       Date:  2011

8.  An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide.

Authors:  Silvia Bolognin; Julie Blanchard; Xiaochuan Wang; Gustavo Basurto-Islas; Yunn Chyn Tung; Erik Kohlbrenner; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Acta Neuropathol       Date:  2011-11-15       Impact factor: 17.088

9.  Methamphetamine augment HIV-1 Tat mediated memory deficits by altering the expression of synaptic proteins and neurotrophic factors.

Authors:  Anantha Ram Nookala; Daniel C Schwartz; Nitish S Chaudhari; Alexy Glazyrin; Edward B Stephens; Nancy E J Berman; Anil Kumar
Journal:  Brain Behav Immun       Date:  2018-05-02       Impact factor: 7.217

10.  Nano to micro delivery systems: targeting angiogenesis in brain tumors.

Authors:  Ariel Gilert; Marcelle Machluf
Journal:  J Angiogenes Res       Date:  2010-10-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.